Court ruling against FDA on off-label promotion could negate new proposals
This article was originally published in Clinica
A US federal judge has ruled that the FDA's policy blocking medical device and pharmaceutical makers from distributing information on unapproved or off-label uses of their products is a violation of the First Amendment guaranteeing free speech.
You may also be interested in...
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.
The US Medicare agency is letting ambulatory surgical centers and patient homes be reimbursed as in-patient hospitals for patient care purposes during the pandemic.
The European public assessment report for Novartis's advanced breast cancer therapy, Piqray (alpelisib), includes some interesting insights into what EU regulators are looking for in drug company clinical trials.